DUBLIN–(BUSINESS WIRE)–Research and Markets (http:\/\/www.researchandmarkets.com\/research\/fv6qlb\/hairy_cell)
\n has announced the addition of the Hairy
\n Cell Leukemia – Pipeline Review, H1 2015 report to their
\n offering.\n <\/p>\n
\n<\/blockquote>\n\n This report provides comprehensive information on the therapeutic
\n development for Hairy Cell Leukemia, complete with comparative analysis
\n at various stages, therapeutics assessment by drug target, mechanism of
\n action (MoA), route of administration (RoA) and molecule type, along
\n with latest updates, and featured news and press releases. It also
\n reviews key players involved in the therapeutic development for Hairy
\n Cell Leukemia and special features on late-stage and discontinued
\n projects.\n <\/p>\n\n The report enhances decision making capabilities and help to create
\n effective counter strategies to gain competitive advantage. It
\n strengthens Ramp;D pipelines by identifying new targets and MOAs to produce
\n first-in-class and best-in-class products.\n <\/p>\n\n Scope\n <\/p>\n
\n – The report provides a snapshot of the global therapeutic landscape of
\n Hairy Cell Leukemia\n <\/p>\n\n – The report reviews key pipeline products under drug profile section
\n which includes, product description, MoA and Ramp;D brief, licensing and
\n collaboration details amp; other developmental activities\n <\/p>\n\n – The report reviews key players involved in the therapeutics
\n development for Hairy Cell Leukemia and enlists all their major and
\n minor projects\n <\/p>\n\n – The report summarizes all the dormant and discontinued pipeline
\n projects\n <\/p>\n\n – A review of the Hairy Cell Leukemia products under development by
\n companies and universities\/research institutes based on information
\n derived from company and industry-specific sources\n <\/p>\n\n – Pipeline products coverage based on various stages of development
\n ranging from pre-registration till discovery and undisclosed stages\n <\/p>\n\n – A detailed assessment of monotherapy and combination therapy pipeline
\n projects\n <\/p>\n\n – Coverage of the Hairy Cell Leukemia pipeline on the basis of target,
\n MoA, route of administration and molecule type\n <\/p>\n\n – Latest news and deals relating related to pipeline products\n <\/p>\n
\n Companies Mentioned\n <\/p>\n
\n – Astellas Pharma Inc.\n <\/p>\n
\n – AstraZeneca PLC\n <\/p>\n
\n – Biogenomics Limited\n <\/p>\n
\n – F. Hoffmann-La Roche Ltd.\n <\/p>\n
\n – GlaxoSmithKline plc\n <\/p>\n
\n – Inbiopro Solutions Pvt. Ltd.\n <\/p>\n
\n – Incyte Corporation\n <\/p>\n
\n – MedImmune, LLC\n <\/p>\n
\n – Plexxikon Inc.\n <\/p>\n
\n For more information visit http:\/\/www.researchandmarkets.com\/research\/fv6qlb\/hairy_cell\n <\/p>\n<\/p>\n